PARP1 expression in pediatric central nervous system tumors

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1227-1230

  Barton, Valerie N ^a,b   Donson, Andrew M ^a,b   Kleinschmidt DeMasters, B K ^c,d   Gore, Lia ^a,b   Liu, Arthur K ^d   Foreman, Nicholas K ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Microarray; PARP1; PARP1 inhibitor; Pediatric brain tumor

Indexed keywords

MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; RNA; TUMOR PROTEIN;

ARTICLE; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM TUMOR; CHOROID PLEXUS PAPILLOMA; CONTROLLED STUDY; EPENDYMOMA; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; TERATOMA; BIOSYNTHESIS; CHILD; CHOROID PLEXUS TUMOR; DNA DAMAGE; DNA MICROARRAY; DNA REPAIR; DRUG DELIVERY SYSTEM; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PAPILLOMA; PATHOLOGY; SINGLE BLIND PROCEDURE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHOROID PLEXUS NEOPLASMS; DNA DAMAGE; DNA REPAIR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; NEOPLASM PROTEINS; NEUROECTODERMAL TUMORS, PRIMITIVE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMA; POLY(ADP-RIBOSE) POLYMERASES; RNA, MESSENGER; RNA, NEOPLASM; SINGLE-BLIND METHOD;

EID: 70449719266     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22141     Document Type: Article

References (19)

1. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
2. Schreiber V, Ame JC, Dolle P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002;277:23028-23036.
3. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999;286:1897-1905.
4. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-1388.
5. Tomoda T, Kurashige T, Moriki T, et al. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991;37:223-227.
6. Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:338-344.
7. Fukushima M, Kuzuya K, Ota K, et al. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett 1981;14:227-236.
8. Alderson T. New targets for cancer chemotherapy-poly(ADP-ribosylation) processing and polyisoprene metabolism. Biol Rev Camb Philos Soc 1990;65:623-641.
9. Wielckens K, Garbrecht M, Kittler M, et al. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem 1980;104:279-287.
10. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997;94:7303-7307.
11. Molinete M, Vermeulen W, Burkle A, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 1993;12:2109-2117.
12. Bowman KJ, White A, Golding BT, et al. Potentiation of anticancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998;78:1269-1277.
13. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
14. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-2737.
15. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-5379.
16. Kleihues P, Cavenee WK, editors.WHOClassification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2007.
17. Donson AM, Erwin NS, Kleinschmidt-DeMasters BK, et al. Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol 2007;66:740-749.
18. Zhijin W, Rafael AI, Robert G, et al. A model-based background adjustment for oligonucleotide expression arrays. J Am Statist Assoc 2004;99:909-917.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.